The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1245 Weight Loss articles
Media mogul Oprah Winfrey has openly discussed her use of GLP-1 drugs for shedding pounds, but she recently shared a surprising outcome: the end of her alcohol consumption. This change has revitalized her sense of vitality and openness, while offering insights into obesity and personal growth. She encourages others to embrace available options without self-blame.
Oprah Winfrey credits her longtime partner Stedman Graham with unwavering support during her health and weight loss efforts. In a recent interview, she detailed how their bond strengthened as she shed pounds with the aid of medication. The media mogul emphasized ending self-shaming and embracing vitality.
Injectable GLP-1 medications have revolutionized obesity management, and now an oral option is emerging. The FDA has approved a pill version of semaglutide for weight loss and cardiovascular risk reduction.
A recent study from Cornell University highlights the profound impact of weight-loss medications such as Ozempic on grocery shopping behaviors in the US. Researchers analyzed data from over 150,000 households, revealing substantial changes in spending on various food items following GLP-1 usage. These findings underscore broader trends in consumer demand influenced by these popular drugs.
GLP-1 medications have surged in popularity for weight management, yet many seniors discontinue them due to significant hurdles. A major study revealed high dropout rates, with older adults particularly affected by factors like cost and adverse reactions. Experts emphasize the need for personalized care to maintain treatment success.
This article explores the growing prevalence of weight-loss injections such as Ozempic in everyday life. It highlights rising adoption rates in the UK and US, potentially transforming workplace dynamics. Key statistics from research providers underscore the trend.
Over 500,000 Californians may lose access to popular GLP-1 weight loss drugs from January 1, 2026, as the state opts out of covering these prescriptions under Medi-Cal for non-medical purposes. The move targets cost savings after federal cuts, while allowing coverage for diabetes and other conditions.
A novel CMS demonstration program seeks to broaden access to GLP-1 receptor agonists for individuals in Medicare Part D and Medicaid, aiming to address weight management and metabolic health. While it promises negotiations with manufacturers for reduced prices, experts remain skeptical about its widespread effectiveness. The initiative builds on prior drug pricing efforts and includes provisions for lifestyle support, with launch timelines set for 2026.
Novo Nordisk has faced challenges with its stock and leadership due to the weight loss drug market. While scientists see potential in GLP-1 medications expanding beyond diabetes and obesity, investors are losing patience. Ongoing research highlights additional benefits like reducing cravings and aiding brain functions.
